Amori, Renee E., Joseph Lau, and Anastassios G. Pittas, ‘Efficacy and Safety of Incretin Therapy in Type 2 Diabetes’, JAMA, 298.2 (2007) <https://doi.org/10.1001/jama.298.2.194>
Amy Kennedy, ‘Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis’, PLoS ONE, 8.3 (2013) <https://doi.org/doi: 10.1371/journal.pone.0058861>
Anderson, Bob, Martha Funnell, and American Diabetes Association, The Art of Empowerment: Stories and Strategies for Diabetes Educators, 2nd ed (Alexandria, Va: American Diabetes Association, 2005)
Anthony H. Barnett, Jenny Grice, New Mechanisms in Glucose Control (BMJ Books; 1 edition, 2013) <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>
‘[ARCHIVED CONTENT] Medicines Management: Everybody’s Business : Department of Health - Publications and Statistics’ <http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200>
Ashwell, S. G., S. A. Amiel, R. W. Bilous, U. Dashora, S. R. Heller, D. A. Hepburn, and others, ‘Improved Glycaemic Control with Insulin Glargine plus Insulin Lispro: A Multicentre, Randomized, Cross-over Trial in People with Type 1 Diabetes’, Diabetic Medicine, 23.3 (2006), 285–92 <https://doi.org/10.1111/j.1464-5491.2005.01781.x>
Atkinson, M. A., ‘The Pathogenesis and Natural History of Type 1 Diabetes’, Cold Spring Harbor Perspectives in Medicine, 2.11 (2012), a007641–a007641 <https://doi.org/10.1101/cshperspect.a007641>
Avery, L., D. Flynn, A. van Wersch, F. F. Sniehotta, and M. I. Trenell, ‘Changing Physical Activity Behavior in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Behavioral Interventions’, Diabetes Care, 35.12 (2012), 2681–89 <https://doi.org/10.2337/dc11-2452>
Bailey, Clifford J, Jorge L Gross, Anne Pieters, Arnaud Bastien, and James F List, ‘Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial’, The Lancet, 375.9733 (2010), 2223–33 <https://doi.org/10.1016/S0140-6736(10)60407-2>
Barry, Vaughn W., Meghan Baruth, Michael W. Beets, J. Larry Durstine, Jihong Liu, and Steven N. Blair, ‘Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis’, Progress in Cardiovascular Diseases, 56.4 (2014), 382–90 <https://doi.org/10.1016/j.pcad.2013.09.002>
Bennett, Wendy L., Nisa M. Maruthur, Sonal Singh, Jodi B. Segal, Lisa M. Wilson, Ranee Chatterjee, and others, ‘Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations’, Annals of Internal Medicine, 154.9 (2011) <https://doi.org/10.7326/0003-4819-154-9-201105030-00336>
Bethel, M. Angelyn, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, and others, ‘Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)’, Diabetes Care, 2017 <https://doi.org/10.2337/dc16-1135>
Beverley M Shields, ‘Can Clinical Features Be Used to Differentiate Type 1 from Type 2 Diabetes? A Systematic Review of the Literature’, BMJ Open, 5.11 (2015) <https://doi.org/doi: 10.1136/bmjopen-2015-009088>
Birkeland, Kåre I, ‘Hyperglycaemia in Pregnancy: Still a Lot to Learn’, The Lancet Diabetes & Endocrinology, 3.10 (2015), 752–53 <https://doi.org/10.1016/S2213-8587(15)00282-X>
Bretzel, Reinhard G, Ulrike Nuber, Wolfgang Landgraf, David R Owens, Clare Bradley, and Thomas Linn, ‘Once-Daily Basal Insulin Glargine versus Thrice-Daily Prandial Insulin Lispro in People with Type 2 Diabetes on Oral Hypoglycaemic Agents (APOLLO): An Open Randomised Controlled Trial’, The Lancet, 371.9618 (2008), 1073–84 <https://doi.org/10.1016/S0140-6736(08)60485-7>
Brown, Julie, Nisreen A Alwan, Jane West, Stephen Brown, Christopher JD McKinlay, Diane Farrar, and others, ‘Lifestyle Interventions for the Treatment of Women with Gestational Diabetes’, in Cochrane Database of Systematic Reviews (Chichester, UK: John Wiley & Sons, Ltd, 1996) <https://doi.org/10.1002/14651858.CD011970.pub2>
Buse, J. B., D. J. Drucker, K. L. Taylor, T. Kim, B. Walsh, H. Hu, and others, ‘DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks’, Diabetes Care, 33.6 (2010), 1255–61 <https://doi.org/10.2337/dc09-1914>
Buse, John B., Richard M. Bergenstal, Leonard C. Glass, Cory R. Heilmann, Michelle S. Lewis, Anita Y.M. Kwan, and others, ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’, Annals of Internal Medicine, 154.2 (2011) <https://doi.org/10.7326/0003-4819-154-2-201101180-00300>
Buse, John B, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, and others, ‘Liraglutide Once a Day versus Exenatide Twice a Day for Type 2 Diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label Trial (LEAD-6)’, The Lancet, 374.9683 (2009), 39–47 <https://doi.org/10.1016/S0140-6736(09)60659-0>
Capehorn, M., W. H. Polonsky, S. Edelman, A. Belton, S. Down, V. Gamerman, and others, ‘Challenges Faced by Physicians When Discussing the Type 2 Diabetes Diagnosis with Patients: Insights from a Cross-National Study (IntroDia )’, Diabetic Medicine, 2017 <https://doi.org/10.1111/dme.13357>
Carver, Catherine, ‘Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes’, The Diabetes Educator, 32.6 (2006), 910–17 <https://doi.org/10.1177/0145721706294259>
Celia G. Walker, ‘Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk’, PLoS ONE, 10.7 (2015) <https://doi.org/doi: 10.1371/journal.pone.0131681>
Chatterjee, Sudesna, and Melanie Davies, ‘Type 2 Diabetes: Recent Advances in Diagnosis and Management’, Prescriber, 26.10 (2015), 15–21 <https://doi.org/10.1002/psb.1355>
Chimen, M., A. Kennedy, K. Nirantharakumar, T. T. Pang, R. Andrews, and P. Narendran, ‘What Are the Health Benefits of Physical Activity in Type 1 Diabetes Mellitus? A Literature Review’, Diabetologia, 55.3 (2012), 542–51 <https://doi.org/10.1007/s00125-011-2403-2>
Choudhary, Pratik, Neil R Parrott, Linda Birtles, and Martin K Rutter, ‘Islet Cell Transplantation: Current Status in the UK (2012)’, Practical Diabetes, 29.7 (2012), 280–85 <https://doi.org/10.1002/pdi.1707>
Copeland, K. C., J. Silverstein, K. R. Moore, G. E. Prazar, T. Raymer, R. N. Shiffman, and others, ‘Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents’, PEDIATRICS, 131.2 (2013), 364–82 <https://doi.org/10.1542/peds.2012-3494>
Courtney, Hamish, Rahul Nayar, Chinnadorai Rajeswaran, and Ravi Jandhyala, ‘Long-Term Management of Type 2 Diabetes with Glucagon-like Peptide-1 Receptor Agonists’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10 (2017), 79–87 <https://doi.org/10.2147/DMSO.S126763>
Crasto, Winston, Janet Jarvis, and Melanie J. Davies, Handbook of Insulin Therapies (Switzerland: Adis, 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
———, Handbook of Insulin Therapies (Switzerland: Adis, 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
———, Handbook of Insulin Therapies (Switzerland: Adis, 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
———, Handbook of Insulin Therapies (Switzerland: Adis, 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
———, Handbook of Insulin Therapies (Switzerland: Adis, 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
———, Handbook of Insulin Therapies (Switzerland: Adis, 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
Daly, H, MJ Davies, J Barnett, S Amin, G Gray, J Leonard, and others, ‘Development of a Self-Management Education Module for Those with Type 2 Diabetes on Injectable Therapies’, Practical Diabetes, 32.8 (2015), 305–10 <https://doi.org/10.1002/pdi.1979>
Davies, M., D. Dahl, T. Heise, J. Kiljanski, and C. Mathieu, ‘Introduction of Biosimilar Insulins in Europe’, Diabetic Medicine, 34.10 (2017), 1340–53 <https://doi.org/10.1111/dme.13400>
Davies, M J, S Heller, T C Skinner, M J Campbell, M E Carey, S Cradock, and others, ‘Effectiveness of the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) Programme for People with Newly Diagnosed Type 2 Diabetes: Cluster Randomised Controlled Trial’, BMJ, 336.7642 (2008), 491–95 <https://doi.org/10.1136/bmj.39474.922025.BE>
Davies, M., F. Storms, S. Shutler, M. Bianchi-Biscay, and R. Gomis, ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine’, Diabetes Care, 28.6 (2005), 1282–88 <https://doi.org/10.2337/diacare.28.6.1282>
Davies, Melanie J., and Sudesna Chatterjee, ‘Trial Watch: Insulin Initiation for Type 2 Diabetes Mellitus in Primary Care’, Nature Reviews Endocrinology, 13.6 (2017), 317–18 <https://doi.org/10.1038/nrendo.2017.41>
Deacon, C. F., and H. E. Lebovitz, ‘Comparative Review of Dipeptidyl Peptidase-4 Inhibitors and Sulphonylureas’, Diabetes, Obesity and Metabolism, 18.4 (2016), 333–47 <https://doi.org/10.1111/dom.12610>
Dhatariya, K. K., C. Skedgel, and R. Fordham, ‘The Cost of Treating Diabetic Ketoacidosis in the UK: A National Survey of Hospital Resource Use’, Diabetic Medicine, 34.10 (2017), 1361–66 <https://doi.org/10.1111/dme.13427>
Diamant, Michaela, Luc Van Gaal, Stephen Stranks, Justin Northrup, Dachuang Cao, Kristin Taylor, and others, ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’, The Lancet, 375.9733 (2010), 2234–43 <https://doi.org/10.1016/S0140-6736(10)60406-0>
———, ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’, The Lancet, 375.9733 (2010), 2234–43 <https://doi.org/10.1016/S0140-6736(10)60406-0>
Dungan, Kathleen M, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, and others, ‘Once-Weekly Dulaglutide versus Once-Daily Liraglutide in Metformin-Treated Patients with Type 2 Diabetes (AWARD-6): A Randomised, Open-Label, Phase 3, Non-Inferiority Trial’, The Lancet, 384.9951 (2014), 1349–57 <https://doi.org/10.1016/S0140-6736(14)60976-4>
‘Effects of Intensive Glucose Control on Microvascular Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomised Controlled Trials- ClinicalKey’ <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null>
‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, 375.18 (2016), 1799–1802 <https://doi.org/10.1056/NEJMc1611290>
Evans, M., P. M. Schumm-Draeger, J. Vora, and A. B. King, ‘A Review of Modern Insulin Analogue Pharmacokinetic and Pharmacodynamic Profiles in Type 2 Diabetes: Improvements and Limitations’, Diabetes, Obesity and Metabolism, 13.8 (2011), 677–84 <https://doi.org/10.1111/j.1463-1326.2011.01395.x>
Frandsen, C. S. S., and S. Madsbad, ‘Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors as an Add-on to Insulin Treatment in Patients with Type 2 Diabetes: A Review’, Diabetic Medicine, 31.11 (2014), 1293–1300 <https://doi.org/10.1111/dme.12561>
Funnell, M. M., ‘Overcoming Barriers to the Initiation of Insulin Therapy’, Clinical Diabetes, 25.1 (2007), 36–38 <https://doi.org/10.2337/diaclin.25.1.36>
Gallwitz, Baptist, Julio Rosenstock, Thomas Rauch, Sudipta Bhattacharya, Sanjay Patel, Maximilian von Eynatten, and others, ‘2-Year Efficacy and Safety of Linagliptin Compared with Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Randomised, Double-Blind, Non-Inferiority Trial’, The Lancet, 380.9840 (2012), 475–83 <https://doi.org/10.1016/S0140-6736(12)60691-6>
Garber, A. J., J. Wahlen, T. Wahl, P. Bressler, R. Braceras, E. Allen, and others, ‘Attainment of Glycaemic Goals in Type 2 Diabetes with Once-, Twice-, or Thrice-Daily Dosing with Biphasic Insulin Aspart 70/30 (The 1-2-3 Study)’, Diabetes, Obesity and Metabolism, 8.1 (2006), 58–66 <https://doi.org/10.1111/j.1463-1326.2005.00563.x>
Garber, Alan J, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, and others, ‘Insulin Degludec, an Ultra-Longacting Basal Insulin, versus Insulin Glargine in Basal-Bolus Treatment with Mealtime Insulin Aspart in Type 2 Diabetes (BEGIN Basal-Bolus Type 2): A Phase 3, Randomised, Open-Label, Treat-to-Target Non-Inferiority Trial’, The Lancet, 379.9825 (2012), 1498–1507 <https://doi.org/10.1016/S0140-6736(12)60205-0>
Garber, Alan J., Robert Ligthelm, Jens S. Christiansen, and Andreas Liebl, ‘Premixed Insulin Treatment for Type 2 Diabetes: Analogue or Human?’, Diabetes, Obesity and Metabolism, 9.5 (2007), 630–39 <https://doi.org/10.1111/j.1463-1326.2006.00654.x>
Gough, S. C. L., S. Harris, V. Woo, and M. Davies, ‘Insulin Degludec: Overview of a Novel Ultra Long-Acting Basal Insulin’, Diabetes, Obesity and Metabolism, 15.4 (2013), 301–9 <https://doi.org/10.1111/dom.12052>
Gough, Stephen C.L., ‘A Review of Human and Analogue Insulin Trials’, Diabetes Research and Clinical Practice, 77.1 (2007), 1–15 <https://doi.org/10.1016/j.diabres.2006.10.015>
Grammes, J., W. Stock, C. G. Mann, E. M. Flynn, and T. Kubiak, ‘Focus Group Study to Identify the Central Facets of Fear of Hypoglycaemia in People with Type 2 Diabetes Mellitus’, Diabetic Medicine, 2017 <https://doi.org/10.1111/dme.13506>
Gray, L. J., K. Khunti, C. Edwardson, S. Goldby, J. Henson, D. H. Morris, and others, ‘Implementation of the Automated Leicester Practice Risk Score in Two Diabetes Prevention Trials Provides a High Yield of People with Abnormal Glucose Tolerance’, Diabetologia, 55.12 (2012), 3238–44 <https://doi.org/10.1007/s00125-012-2725-8>
Gray, L.J., K. Khunti, E.G. Wilmot, T. Yates, and M.J. Davies, ‘External Validation of Two Diabetes Risk Scores in a Young UK South Asian Population’, Diabetes Research and Clinical Practice, 104.3 (2014), 451–58 <https://doi.org/10.1016/j.diabres.2014.03.018>
Green, Jennifer B., M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, and others, ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 373.3 (2015), 232–42 <https://doi.org/10.1056/NEJMoa1501352>
Gururaj Setty, S, W Crasto, J Jarvis, K Khunti, and M J Davies, ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’, Postgraduate Medical Journal, 92.1085 (2016), 152–64 <https://doi.org/10.1136/postgradmedj-2015-133716>
———, ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’, Postgraduate Medical Journal, 92.1085 (2016), 152–64 <https://doi.org/10.1136/postgradmedj-2015-133716>
Hadjiconstantinou, Michelle, Jo Byrne, Danielle H Bodicoat, Noelle Robertson, Helen Eborall, Kamlesh Khunti, and others, ‘Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis’, Journal of Medical Internet Research, 18.10 (2016) <https://doi.org/10.2196/jmir.5991>
Hartman, Yvonne A.W., Henry J. Jansen, Maria T.E. Hopman, Cees J. Tack, and Dick H.J. Thijssen, ‘Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior’, Diabetes Care, 40.9 (2017), e120–21 <https://doi.org/10.2337/dc17-0787>
Heinonen, I, H Helajärvi, K Pahkala, O J Heinonen, M Hirvensalo, K Pälve, and others, ‘Sedentary Behaviours and Obesity in Adults: The Cardiovascular Risk in Young Finns Study’, BMJ Open, 3.6 (2013) <https://doi.org/10.1136/bmjopen-2013-002901>
Heller, S. R., S. Colagiuri, S. Vaaler, B. H. R. Wolffenbuttel, K. Koelendorf, H. H. Friberg, and others, ‘Hypoglycaemia with Insulin Aspart: A Double-Blind, Randomised, Crossover Trial in Subjects with Type 1 Diabetes’, Diabetic Medicine, 21.7 (2004), 769–75 <https://doi.org/10.1111/j.1464-5491.2004.01244.x>
Henson, Joseph, ‘Associations of Sedentary Time with Fat Distribution in a High-Risk Population.’, 2014 <https://lra.le.ac.uk/handle/2381/32505>
Hermansen, K., M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, and P. Home, ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’, Diabetes Care, 29.6 (2006), 1269–74 <https://doi.org/10.2337/dc05-1365>
Holman, R. R., and R. C. Turner, ‘A Practical Guide to Basal and Prandial Insulin Therapy’, Diabetic Medicine, 2.1 (1985), 45–53 <https://doi.org/10.1111/j.1464-5491.1985.tb00592.x>
Holman, Rury R., Kerensa I. Thorne, Andrew J. Farmer, Melanie J. Davies, Joanne F. Keenan, Sanjoy Paul, and others, ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’, New England Journal of Medicine, 357.17 (2007), 1716–30 <https://doi.org/10.1056/NEJMoa075392>
Home, P. D., ‘The Pharmacokinetics and Pharmacodynamics of Rapid-Acting Insulin Analogues and Their Clinical Consequences’, Diabetes, Obesity and Metabolism, 14.9 (2012), 780–88 <https://doi.org/10.1111/j.1463-1326.2012.01580.x>
Horvath, Karl, Klaus Jeitler, Andrea Berghold, Susanne H Ebrahim, Thomas W Gratzer, Johannes Plank, and others, ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’, in Cochrane Database of Systematic Reviews (Chichester, UK: John Wiley & Sons, Ltd, 1996) <https://doi.org/10.1002/14651858.CD005613.pub3>
———, ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’, in Cochrane Database of Systematic Reviews (Chichester, UK: John Wiley & Sons, Ltd, 1996) <https://doi.org/10.1002/14651858.CD005613.pub3>
Htike, Zin Z., Francesco Zaccardi, Dimitris Papamargaritis, David R. Webb, Kamlesh Khunti, and Melanie J. Davies, ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis’, Diabetes, Obesity and Metabolism, 19.4 (2017), 524–36 <https://doi.org/10.1111/dom.12849>
———, ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis’, Diabetes, Obesity and Metabolism, 19.4 (2017), 524–36 <https://doi.org/10.1111/dom.12849>
Htike, Zin Zin, Francesco Zaccardi, Sudesna Chatterjee, Kamlesh Khunti, and Melanie J Davies, ‘Glucagon like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Management of Type 2 Diabetes: Choosing the Right Agent for Individualised Care’, British Journal of Diabetes, 16.3 (2016) <https://doi.org/10.15277/bjd.2016.091>
Inzucchi, Silvio E., Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, and others, ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, 38.1 (2015), 140–49 <https://doi.org/10.2337/dc14-2441>
Ismail-Beigi, Faramarz, ‘Glycemic Management of Type 2 Diabetes Mellitus’, New England Journal of Medicine, 366.14 (2012), 1319–27 <https://doi.org/10.1056/NEJMcp1013127>
John M Jakicic, ‘Physical Activity Considerations for the Treatment and Prevention of Obesity’, The American Journal of Clinical Nutrition, 82.1 (2005), 226S-229S <http://ajcn.nutrition.org/content/82/1/226S>
Johnston, Bradley C., Steve Kanters, Kristofer Bandayrel, Ping Wu, Faysal Naji, Reed A. Siemieniuk, and others, ‘Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults’, JAMA, 312.9 (2014) <https://doi.org/10.1001/jama.2014.10397>
Jones, A. G., and A. T. Hattersley, ‘The Clinical Utility of C-Peptide Measurement in the Care of Patients with Diabetes’, Diabetic Medicine, 30.7 (2013), 803–17 <https://doi.org/10.1111/dme.12159>
Kamlesh Khunti, ‘Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes’, PLoS ONE, 10.9 (2015) <https://doi.org/doi: 10.1371/journal.pone.0135702>
Kenneth Hodson, ‘Gestational Diabetes: Emerging Concepts in Pathophysiology’, Obstetric Medicine, 3.4 (2010) <https://doi.org/doi: 10.1258/om.2010.100025>
Latika Sahu, ‘Comparison of the American Diabetes Association and World Health Organization Criteria for Gestational Diabetes Mellitus and the Outcomes of Pregnancy’, Obstetric Medicine, 2.4 (2009) <https://doi.org/doi: 10.1258/om.2009.080049>
Lee, I-Min, ‘Physical Activity and Weight Gain Prevention’, JAMA, 303.12 (2010) <https://doi.org/10.1001/jama.2010.312>
Leff, D. R., and D. Heath, ‘Surgery for Obesity in Adulthood’, BMJ, 339.sep22 1 (2009), b3402–b3402 <https://doi.org/10.1136/bmj.b3402>
Levin, Philip A, Hiep Nguyen, Eric Wittbrodt, and Seoyoung C. Kim, ‘Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review of Comparative Effectiveness Research’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10 (2017), 123–39 <https://doi.org/10.2147/DMSO.S130834>
‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 375.18 (2016), 1797–99 <https://doi.org/10.1056/NEJMc1611289>
Mäkimattila, S., K. Nikkilä, and H. Yki-Järvinen, ‘Causes of Weight Gain during Insulin Therapy with and without Metformin in Patients with Type II Diabetes Mellitus’, Diabetologia, 42.4 (1999), 406–12 <https://doi.org/10.1007/s001250051172>
Marre, M., J. Shaw, M. Brändle, W. M. W. Bebakar, N. A. Kamaruddin, J. Strand, and others, ‘Liraglutide, a Once-Daily Human GLP-1 Analogue, Added to a Sulphonylurea over 26 Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared with Adding Rosiglitazone or Placebo in Subjects with Type 2 Diabetes (LEAD-1 SU)’, Diabetic Medicine, 26.3 (2009), 268–78 <https://doi.org/10.1111/j.1464-5491.2009.02666.x>
Marso, Steven P., Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, and others, ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, 375.19 (2016), 1834–44 <https://doi.org/10.1056/NEJMoa1607141>
Marso, Steven P., Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F.E. Mann, Michael A. Nauck, and others, ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 375.4 (2016), 311–22 <https://doi.org/10.1056/NEJMoa1603827>
———, ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 375.4 (2016), 311–22 <https://doi.org/10.1056/NEJMoa1603827>
Merlin C. Thomas, ‘Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment’, Diabetes Therapy, 7.3 (2016) <https://doi.org/doi: 10.1007/s13300-016-0189-4>
Michael Riddell, ‘Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring’, Journal of Diabetes Science and Technology (Online), 3.4 (2009) <https://doi.org/doi: 10.1177/193229680900300439>
Min, Se Hee, Jeong-Hwa Yoon, Seokyung Hahn, and Young Min Cho, ‘Comparison between SGLT2 Inhibitors and DPP4 Inhibitors Added to Insulin Therapy in Type 2 Diabetes: A Systematic Review with Indirect Comparison Meta-Analysis’, Diabetes/Metabolism Research and Reviews, 33.1 (2017) <https://doi.org/10.1002/dmrr.2818>
‘Minimizing Hypoglycemia in Diabetes: Table 1’, Diabetes Care, 38.8 (2015), 1583–91 <https://doi.org/10.2337/dc15-0279>
Mishriky, Basem M., Doyle M. Cummings, and Robert J. Tanenberg, ‘The Efficacy and Safety of DPP4 Inhibitors Compared to Sulfonylureas as Add-on Therapy to Metformin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis’, Diabetes Research and Clinical Practice, 109.2 (2015), 378–88 <https://doi.org/10.1016/j.diabres.2015.05.025>
———, ‘The Efficacy and Safety of DPP4 Inhibitors Compared to Sulfonylureas as Add-on Therapy to Metformin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis’, Diabetes Research and Clinical Practice, 109.2 (2015), 378–88 <https://doi.org/10.1016/j.diabres.2015.05.025>
Moreno-Castilla, Cristina, Didac Mauricio, and Marta Hernandez, ‘Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus’, Current Diabetes Reports, 16.4 (2016) <https://doi.org/10.1007/s11892-016-0717-7>
Nathan, D. M., J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and others, ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, 29.8 (2006), 1963–72 <https://doi.org/10.2337/dc06-9912>
Nauck, M., ‘Incretin Therapies: Highlighting Common Features and Differences in the Modes of Action of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors’, Diabetes, Obesity and Metabolism, 18.3 (2016), 203–16 <https://doi.org/10.1111/dom.12591>
Nauck, M. A., G. Meininger, D. Sheng, L. Terranella, and P. P. Stein, ‘Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Compared with the Sulfonylurea, Glipizide, in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone: A Randomized, Double-Blind, Non-Inferiority Trial’, Diabetes, Obesity and Metabolism, 9.2 (2007), 194–205 <https://doi.org/10.1111/j.1463-1326.2006.00704.x>
Nauck, Michael A, and Juris J Meier, ‘The Incretin Effect in Healthy Individuals and Those with Type 2 Diabetes: Physiology, Pathophysiology, and Response to Therapeutic Interventions’, The Lancet Diabetes & Endocrinology, 4.6 (2016), 525–36 <https://doi.org/10.1016/S2213-8587(15)00482-9>
Nauck, Michael, Ruth S. Weinstock, Guillermo E. Umpierrez, Bruno Guerci, Zachary Skrivanek, and Zvonko Milicevic, ‘Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)’, Diabetes Care, 37.8 (2014), 2149–58 <https://doi.org/10.2337/dc13-2761>
Nissen, Steven E., and Kathy Wolski, ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’, New England Journal of Medicine, 356.24 (2007), 2457–71 <https://doi.org/10.1056/NEJMoa072761>
Nolan, Christopher J., Neil B. Ruderman, Steven E. Kahn, Oluf Pedersen, and Marc Prentki, ‘Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes’, Diabetes, 64.3 (2015), 673–86 <https://doi.org/10.2337/db14-0694>
Paul Craddy, ‘Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison’, Diabetes Therapy, 5.1 (2014) <https://doi.org/doi: 10.1007/s13300-014-0061-3>
Persaud, Shanta J., and Peter M. Jones, ‘A Wake-up Call for Type 2 Diabetes?’, New England Journal of Medicine, 375.11 (2016), 1090–92 <https://doi.org/10.1056/NEJMcibr1607950>
‘Postnatal Testing Following Gestational Diabetes- ClinicalKey’ <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null>
‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’, 4AD <https://www.youtube.com/watch?v=AhhWTmEFuag>
Qin, Li, Mirjam J. Knol, Eva Corpeleijn, and Ronald P. Stolk, ‘Does Physical Activity Modify the Risk of Obesity for Type 2 Diabetes: A Review of Epidemiological Data’, European Journal of Epidemiology, 25.1 (2010), 5–12 <https://doi.org/10.1007/s10654-009-9395-y>
Raskin, P., E. Allen, P. Hollander, A. Lewin, R. A. Gabbay, P. Hu, and others, ‘Initiating Insulin Therapy in Type 2 Diabetes: A Comparison of Biphasic and Basal Insulin Analogs’, Diabetes Care, 28.2 (2005), 260–65 <https://doi.org/10.2337/diacare.28.2.260>
‘Resources and Tools’ <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html>
‘———’ <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html>
‘———’ <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html>
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein, Textbook of Diabetes (John Wiley, 2016) <https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056>
Richter, Bernd, and Gudrun Neises, ‘“Human” Insulin versus Animal Insulin in People with Diabetes Mellitus’, in Cochrane Database of Systematic Reviews (Chichester, UK: John Wiley & Sons, Ltd, 1996) <https://doi.org/10.1002/14651858.CD003816.pub2>
Riddle, M. C., R. Aronson, P. Home, M. Marre, E. Niemoeller, P. Miossec, and others, ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-Week, Randomized, Placebo-Controlled Comparison (GetGoal-L)’, Diabetes Care, 36.9 (2013), 2489–96 <https://doi.org/10.2337/dc12-2454>
Rinki Murphy, ‘Monogenic Diabetes and Pregnancy’, Obstetric Medicine, 8.3 (2015) <https://doi.org/doi: 10.1177/1753495X15590713>
Rizos, Christos V., Anastazia Kei, and Moses S. Elisaf, ‘The Current Role of Thiazolidinediones in Diabetes Management’, Archives of Toxicology, 90.8 (2016), 1861–81 <https://doi.org/10.1007/s00204-016-1737-4>
Rosenstock, J., M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, ‘A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-on to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes’, Diabetologia, 51.3 (2008), 408–16 <https://doi.org/10.1007/s00125-007-0911-x>
Rosenstock, J., D. Raccah, L. Koranyi, L. Maffei, G. Boka, P. Miossec, and others, ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-Week, Randomized, Open-Label, Active-Controlled Study (GetGoal-X)’, Diabetes Care, 36.10 (2013), 2945–51 <https://doi.org/10.2337/dc12-2709>
Rotz, M. E., V. S. Ganetsky, S. Sen, and T. F. Thomas, ‘Implications of Incretin-Based Therapies on Cardiovascular Disease’, International Journal of Clinical Practice, 69.5 (2015), 531–49 <https://doi.org/10.1111/ijcp.12572>
Ryder, Bob, John McKnight, Andrew Blann, Ketan Dhatariya, Rob Gregory, Tony Robinson, and others, ‘ABCD Position Statement on GLP-1 Based Therapies and Pancreatic Damage’, Practical Diabetes, 30.9 (2013), 388–91 <https://doi.org/10.1002/pdi.1816>
S M Attard, ‘Implications of Iron Deficiency/Anemia on the Classification of Diabetes Using HbA1c’, Nutrition & Diabetes, 5.6 (2015) <https://doi.org/doi: 10.1038/nutd.2015.16>
‘Safety and Insulin: Implementation of National Guidance at a Local Level | Journal Content | Diabetesonthenet.Com’ <http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level>
Sallis, James F, Fiona Bull, Regina Guthold, Gregory W Heath, Shigeru Inoue, Paul Kelly, and others, ‘Progress in Physical Activity over the Olympic Quadrennium’, The Lancet, 388.10051 (2016), 1325–36 <https://doi.org/10.1016/S0140-6736(16)30581-5>
Samuel, Varman T., and Gerald I. Shulman, ‘Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links’, Cell, 148.5 (2012), 852–71 <https://doi.org/10.1016/j.cell.2012.02.017>
Schauer, Philip R., Deepak L. Bhatt, John P. Kirwan, Kathy Wolski, Ali Aminian, Stacy A. Brethauer, and others, ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’, New England Journal of Medicine, 376.7 (2017), 641–51 <https://doi.org/10.1056/NEJMoa1600869>
Schauer, Philip R., Sangeeta R. Kashyap, Kathy Wolski, Stacy A. Brethauer, John P. Kirwan, Claire E. Pothier, and others, ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’, New England Journal of Medicine, 366.17 (2012), 1567–76 <https://doi.org/10.1056/NEJMoa1200225>
———, ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’, New England Journal of Medicine, 366.17 (2012), 1567–76 <https://doi.org/10.1056/NEJMoa1200225>
Schwartz, Stanley S., Solomon Epstein, Barbara E. Corkey, Struan F.A. Grant, James R. Gavin, and Richard B. Aguilar, ‘The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema’, Diabetes Care, 39.2 (2016), 179–86 <https://doi.org/10.2337/dc15-1585>
Simmons, Rebecca K, Knut Borch-Johnsen, Torsten Lauritzen, Guy EHM Rutten, Annelli Sandbæk, Maureen van den Donk, and others, ‘A Randomised Trial of the Effect and Cost-Effectiveness of Early Intensive Multifactorial Therapy on 5-Year Cardiovascular Outcomes in Individuals with Screen-Detected Type 2 Diabetes: The Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) Study’, Health Technology Assessment, 20.64 (2016), 1–86 <https://doi.org/10.3310/hta20640>
Sivasubramaniyam, S., S. A. Amiel, and P. Choudhary, ‘Proportion of Daily Capillary Blood Glucose Readings Required in the Target Range for Target Glycaemic Control: Shift of Focus from Target Range to Proportion in Range’, Diabetic Medicine, 34.10 (2017), 1456–60 <https://doi.org/10.1111/dme.13438>
Sjöström, Lars, Anna-Karin Lindroos, Markku Peltonen, Jarl Torgerson, Claude Bouchard, Björn Carlsson, and others, ‘Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery’, New England Journal of Medicine, 351.26 (2004), 2683–93 <https://doi.org/10.1056/NEJMoa035622>
Srinivasan, B T, J Jarvis, K Khunti, and M J Davies, ‘Recent Advances in the Management of Type 2 Diabetes Mellitus: A Review’, Postgraduate Medical Journal, 84.996 (2008), 524–31 <https://doi.org/10.1136/pgmj.2008.067918>
Srinivasan, Balasubramanian T., and Melanie Davies, ‘Glycaemic Management of Type 2 Diabetes’, Medicine, 42.12 (2014), 711–17 <https://doi.org/10.1016/j.mpmed.2014.09.011>
Srinivasan, P, G C Huang, S A Amiel, and N D Heaton, ‘Islet Cell Transplantation’, Postgraduate Medical Journal, 83.978 (2007), 224–29 <https://doi.org/10.1136/pgmj.2006.053447>
‘Standards of Medical Care in Diabetes--2015: Summary of Revisions’, Diabetes Care, 38.Supplement_1 (2015), S4–S4 <https://doi.org/10.2337/dc15-S003>
Steven, S., and R. Taylor, ‘Restoring Normoglycaemia by Use of a Very Low Calorie Diet in Long- and Short-Duration Type 2 Diabetes’, Diabetic Medicine, 32.9 (2015), 1149–55 <https://doi.org/10.1111/dme.12722>
Steven, Sarah, Kieren G. Hollingsworth, Ahmad Al-Mrabeh, Leah Avery, Benjamin Aribisala, Muriel Caslake, and others, ‘Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders’, Diabetes Care, 39.5 (2016), 808–15 <https://doi.org/10.2337/dc15-1942>
Stewart, Zoe A., Malgorzata E. Wilinska, Sara Hartnell, Rosemary C. Temple, Gerry Rayman, Katharine P. Stanley, and others, ‘Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes’, New England Journal of Medicine, 375.7 (2016), 644–54 <https://doi.org/10.1056/NEJMoa1602494>
Swinnen, Sanne G, Airin CR Simon, Frits Holleman, Joost B Hoekstra, and J Hans DeVries, ‘Insulin Detemir versus Insulin Glargine for Type 2 Diabetes Mellitus’, in Cochrane Database of Systematic Reviews (Chichester, UK: John Wiley & Sons, Ltd, 1996) <https://doi.org/10.1002/14651858.CD006383.pub2>
Tanner, Michael, ‘Review: In Type 2 Diabetes, Adding Dipeptidyl Peptidase-4 Inhibitors to Sulphonylureas Increases Hypoglycemia’, Annals of Internal Medicine, 165.4 (2016) <https://doi.org/10.7326/ACPJC-2016-165-4-020>
Tao, L., E. C. F. Wilson, N. J. Wareham, A. Sandbaek, G. E. H. M. Rutten, T. Lauritzen, and others, ‘Cost-Effectiveness of Intensive Multifactorial Treatment Compared with Routine Care for Individuals with Screen-Detected Type 2 Diabetes: Analysis of the ADDITION-UK Cluster-Randomized Controlled Trial’, Diabetic Medicine, 32.7 (2015), 907–19 <https://doi.org/10.1111/dme.12711>
‘Type 2 Diabetes in Adults: Management | Guidance and Guidelines | NICE’ <https://www.nice.org.uk/guidance/ng28>
Umpierre, Daniel, ‘Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes’, JAMA, 305.17 (2011) <https://doi.org/10.1001/jama.2011.576>
‘Unit 3 – Special Care Groups: A Practical Guide to Pregnancy Complicated by Diabetes - Diabetes & Primary Care’ <http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>
Villani, M., B. de Courten, and S. Zoungas, ‘Emergency Treatment of Hypoglycaemia: A Guideline and Evidence Review’, Diabetic Medicine, 34.9 (2017), 1205–11 <https://doi.org/10.1111/dme.13379>
Vloemans, A. F., C. A. J. van Beers, M. de Wit, W. Cleijne, S. M. Rondags, P. H. Geelhoed-Duijvestijn, and others, ‘Keeping Safe. Continuous Glucose Monitoring (CGM) in Persons with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia: A Qualitative Study’, Diabetic Medicine, 34.10 (2017), 1470–76 <https://doi.org/10.1111/dme.13429>
Wanner, Christoph, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, and others, ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, 375.4 (2016), 323–34 <https://doi.org/10.1056/NEJMoa1515920>
‘WHO 2011 Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus’ <http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/>
Yeh, James S., Robert F. Kushner, and Gordon D. Schiff, ‘Obesity and Management of Weight Loss’, New England Journal of Medicine, 375.12 (2016), 1187–89 <https://doi.org/10.1056/NEJMclde1515935>
Yki-Järvinen, H., R. Kauppinen-Mäkelin, M. Tiikkainen, M. Vähätalo, H. Virtamo, K. Nikkilä, and others, ‘Insulin Glargine or NPH Combined with Metformin in Type 2 Diabetes: The LANMET Study’, Diabetologia, 49.3 (2006), 442–51 <https://doi.org/10.1007/s00125-005-0132-0>
Young, Laura A, and John B Buse, ‘GLP-1 Receptor Agonists and Basal Insulin in Type 2 Diabetes’, The Lancet, 384.9961 (2014), 2180–81 <https://doi.org/10.1016/S0140-6736(14)61409-4>
Young-Hyman, Deborah, Mary de Groot, Felicia Hill-Briggs, Jeffrey S. Gonzalez, Korey Hood, and Mark Peyrot, ‘Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140’, Diabetes Care, 40.2 (2017), 287.1-287 <https://doi.org/10.2337/dc17-er02>
Zaccardi, Francesco, David R Webb, Thomas Yates, and Melanie J Davies, ‘Pathophysiology of Type 1 and Type 2 Diabetes Mellitus: A 90-Year Perspective’, Postgraduate Medical Journal, 92.1084 (2016), 63–69 <https://doi.org/10.1136/postgradmedj-2015-133281>
Zinman, Bernard, Greg Fulcher, Paturi V Rao, Nihal Thomas, Lars A Endahl, Thue Johansen, and others, ‘Insulin Degludec, an Ultra-Long-Acting Basal Insulin, Once a Day or Three Times a Week versus Insulin Glargine Once a Day in Patients with Type 2 Diabetes: A 16-Week, Randomised, Open-Label, Phase 2 Trial’, The Lancet, 377.9769 (2011), 924–31 <https://doi.org/10.1016/S0140-6736(10)62305-7>
